TNF and cardiac sarcoidosis: Certain international consensus guidelines recommend the use of methotrexate and tumor necrosis factor-alpha inhibitors like infliximab or adalimumab in severe or refractory cases of cardiac sarcoidosis, especially as second- and third-line agents, which also aim to minimize steroid exposure.